Literature DB >> 3875464

Lymphocytotoxic antibodies in primary biliary cirrhosis.

A Parés, J Martorell, J Caballería, J Vives, M Bruguera, J Rodés.   

Abstract

Sera of 30 patients with primary biliary cirrhosis (PBC) and 72 normal subjects matched for age and sex were examined for the presence of lymphocytotoxic antibodies (LCAs) against B and T cells at 4 degrees C and 37 degrees C. Patients were prospectively screened for: Sjögren's syndrome, scleroderma, Hashimoto's thyroiditis, and rheumatoid arthritis, in which LCAs have been described. Seventeen patients with PBC (56.6%) had LCAs against B cells as compared with only 11 of the 72 normal subjects (P less than 0.001). Five PBC patients (16.6%) also reacted against T cells as compared with none in control group (P less than 0.01). Clinical and biochemical features and the histological stage of PBC were similar in patients with and without LCA. Sjögren's syndrome was present in 13 patients--two with scleroderma and another with Hashimoto's thyroiditis. No patient had rheumatoid arthritis. The prevalence of LCAs was similar in PBC patients with or without autoimmune associated disease (54% vs 59%). We conclude that in PBC a high incidence of LCA is unrelated to the presence of an associated disease. LCA in PBC might be a nonspecific marker of an immune disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875464     DOI: 10.1007/bf01309512

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Mitochondrial antibody in primary biliary cirrhosis and other diseases.

Authors:  G Klatskin; F S Kantor
Journal:  Ann Intern Med       Date:  1972-10       Impact factor: 25.391

2.  Purification of human T and B lymphocytes.

Authors:  M F Greaves; G Brown
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

3.  Immunoglobulins in chronic liver disease.

Authors:  T Feizi
Journal:  Gut       Date:  1968-04       Impact factor: 23.059

4.  Features of Sjögren's syndrome in primary biliary cirrhosis.

Authors:  D Alarcón-Segovia; E Díaz-Jouanen; E Fishbein
Journal:  Ann Intern Med       Date:  1973-07       Impact factor: 25.391

5.  Circulating IgG complexes in primary biliary cirrhosis. A serial study in forty patients followed for two years.

Authors:  R C Gupta; E R Dickson; F C McDuffie; A H Baggenstoss
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

6.  Peripheral blood lymphocyte populations in chronic liver disease.

Authors:  H C Thomas; M Freni; J Sanchez-Tapias; D de Villiers; S Jain; S Sherlock
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

7.  Lymphocytotoxins in acute and chronic hepatitis. Characterization and relationship to changes in circulating T lymphocytes.

Authors:  R J Dehoratius; C Henderson; R G Strickland
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

8.  Non-HLA lymphocyte cytotoxins in various diseases.

Authors:  G Ozturk; P I Terasaki
Journal:  Tissue Antigens       Date:  1979-07

9.  Lymphocytotoxic antibody in inflammatory bowel disease. A family study.

Authors:  S J Korsmeyer; R C Williams; I D Wilson; R G Strickland
Journal:  N Engl J Med       Date:  1975-11-27       Impact factor: 91.245

10.  Primary biliary cirrhosis: an epidemiological study.

Authors:  D R Triger
Journal:  Br Med J       Date:  1980-09-20
View more
  3 in total

Review 1.  Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

Authors:  Y Bar-Dayan; M E Gershwin; Y Levi; H Amital; Y Shoenfeld
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

2.  Anti-lymphocytic antibodies in autoimmune chronic active hepatitis starting in childhood.

Authors:  P T Donaldson; M J Hussain; G Mieli-Vergani; A P Mowat; D Vergani
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

3.  Serum lymphocytotoxic activity in leprosy.

Authors:  F N Rasheed; M Locniskar; D J McCloskey; R S Hasan; T J Chiang; P Rose; R de Soldenhoff; H Festenstein; K P McAdam
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.